UPMC Hamot Heart and Vascular Institute
UPMC Hamot Heart and Vascular Institute was established as a combined vision of UPMC Hamot, Flagship CVT Surgeons, and Medicor Associates to coordinate and manage the delivery of cardiovascular and thoracic care throughout the Erie region. We strive to be the premier provider of cardiovascular and thoracic services in the Erie region and a leader in heart care as identified by quality, value, and service.
We use outcomes measures to guide improvements in patient care and resource utilization. Our staff is customer-driven and strives to deliver flawless service to our patients and physicians.
The staff of UPMC Hamot Heart and Vascular Institute provides expert cardiovascular care in the areas of:
- Surgery and intervention
- Rehabilitation and restorative medicine
UPMC Hamot Heart and Vascular Institute combines all cardiovascular- and thoracic-related services, including:
- Preventive cardiology
- Clinical research
- Non-invasive and invasive diagnostic services
- Therapeutic interventional and surgical cardiovascular services
- Post-procedure rehabilitation
- Ongoing, long-term management of heart services and its risk factors
We’ve introduced the region’s first valve center, first peripheral vascular center, first heart failure clinic, first cardiac ER, and we are the first to offer transcatheter aortic valve replacement.
During a heart attack, every minute is critical, not only for saving lives, but for salvaging as much of the heart’s function as possible. That’s why UPMC Hamot recently initiated a direct-to-cath lab protocol. People experiencing a heart attack are routed directly to the UPMC Hamot cath lab for immediate intervention and essential treatment, bypassing the Emergency Department altogether. This saves precious time and valuable heart muscle. At UPMC Hamot, our door-to-balloon time average is just 45 minutes, approximately half the national benchmark.
Transcatheter Aortic Valve Replacement (TAVR)
UPMC Hamot is one of only a few providers in the nation approved to perform innovative transcatheter aortic valve replacement (TAVR) procedures, where an artificial aortic valve is implanted inside a patient’s faulty valve, eliminating the need for a heart-lung machine during surgery. This makes the procedure far less risky for higher-risk patients, including those of advanced age or who have health conditions preventing them from undergoing traditional bypass surgery.